

Diabetic Testing Supplies Policy Number: C5108-A

CRITERIA EFFECTIVE DATES:

ORIGINAL EFFECTIVE DATE	LAST REVIEWED DATE	NEXT REVIEW DATE
5/1/2014	3/1/2019	3/1/2020
J CODE	TYPE OF CRITERIA	LAST P&T APPROVAL
	RxPA	Q3

PRODUCTS AFFECTED:

DRUG CLASS:Diagnostic Tests

ROUTE OF ADMINISTRATION: NA

PLACE OF SERVICE:

Retail Pharmacy

AVAILABLE DOSAGE FORMS:

FDA-APPROVED USES: routine blood glucose monitoring

COMPENDIAL APPROVED OFF-LABELED USES: None

COVERAGE CRITERIA: INITIAL AUTHORIZATION

DIAGNOSIS: None required

REQUIRED MEDICAL INFORMATION:

- A. FOR ALL INDICATIONS, FOR NON-FORMULARY METER AND TEST STRIPS, NEEDLES OR SYRINGES:
 - (a) Medically necessary justification (e.g., mental or physical limitation) why the patient needs to remain on their current glucometer/test strip/needle/syringes OR
 - (b) Patient has a physical or mental limitation that requires the use of a specific non-formulary glucometer/test strip/needle/syringes
 - (c) Patient is currently on an insulin pump or an insulin delivery device (e.g., OmniPod) that requires a specific glucometer/test strip

DURATION OF APPROVAL: Initial authorization: 12 months, Continuation of therapy: 12 months

QUANTITY:

Child, Insulin dependent or pregnant patient: 200 strips/30 days, Adult, non-insulin dependent patient: 50 strips/30 days OR documentation describing need for more frequent testing

PRESCRIBER REQUIREMENTS: None

of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

AGE RESTRICTIONS: None

Prior Authorization Criteria



GENDER:

Male and female

CONTINUATION OF THERAPY:

- A. FOR ALL INDICATIONS, FOR NON-FORMULARY METER AND TEST STRIPS, NEEDLES OR SYRINGES:
 - 1. Continues to meet initial criteria

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION: None

OTHER SPECIAL CONSIDERATIONS: None

BACKGROUND:

The American Diabetes Association (ADA) recommends routine blood glucose monitoring in patients using insulin therapy. The ADA also notes that blood glucose monitoring may be helpful to guide treatment decisions for patients using noninsulin therapies. The ADA does not differentiate between brands of diabetic meters or test strips in their recommendation. This program allows members utilizing an insulin pump to continue on their current diabetic meter/test strip if it the diabetic meter/strip is part of the system and interfaces directly with the insulin pump.

APPENDIX: None

REFERENCES:

 American Diabetes Association; Standards of Medical Care in Diabetes – 2017. Diabetes Care 2017: Jan; 40 (Supplement 1): S48-S56

of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.